Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

Trial Profile

Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms FARAONIC
  • Sponsors Bayer
  • Most Recent Events

    • 10 Oct 2019 Status changed from recruiting to active, no longer recruiting.
    • 12 Jul 2019 Planned End Date changed from 30 Aug 2021 to 30 Oct 2021.
    • 12 Jul 2019 Planned primary completion date changed from 28 Jun 2021 to 31 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top